Skip to main content
Caplight Logo









Kekkan Biologics

Kekkan Biologics

Private
StrasbourgHealthcare & Life Scienceshttps://kekkan-biologics.com/

Last Round

Grant

Jul 5, 2023

Total Funding Raised

$670,000

Company Overview

Kekkan Biologics is a biotechnology company that develops first-in-class bispecific antibodies targeting lymphatic and vascular angiogenesis to treat metastatic cancers and fibrotic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverybiologicsvascular medicinetherapeutic candidatespre-clinical researchmonoclonal antibodycardiovascular healthbiotech startuptranslational researchintellectual propertydrug pipelinepharma licensingwet-lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kekkan Biologics Comparables

Compare Kekkan Biologics with similar companies based on industry and business-model similarity.

Kekkan Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Massalia Therapeutics
73%
SPIMA Therapeutics
70%
PharmAbcine Inc.
66%

Kekkan Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 5, 2023

Kekkan Biologics Investors

Notable investors and investment history

Kekkan Biologics investors
InvestorRounds
Landmark BioVentures AGAccelerator
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 5, 2023

    $670K grant received from Bpifrance.

Kekkan Biologics Filings

Explore SEC and related filing metadata, where available.

Kekkan Biologics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kekkan Biologics's valuation, stock price, and market status.

Is Kekkan Biologics a public or private company?

Kekkan Biologics is a private company.

What is the current stock price of Kekkan Biologics?

Kekkan Biologics is a private company with no public stock price. Caplight tracks Kekkan Biologics's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Kekkan Biologics worth (valuation)?

Valuation information for Kekkan Biologics is not publicly available.

Can I buy Kekkan Biologics stock?

Kekkan Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kekkan Biologics's last funding round?

Kekkan Biologics's most recent funding round was Grant on July 5, 2023.

Who are the main investors in Kekkan Biologics?

Key investors in Kekkan Biologics include Landmark BioVentures AG.

Will Kekkan Biologics IPO soon?

No public IPO plans have been announced for Kekkan Biologics.

How can I track Kekkan Biologics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kekkan Biologics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStrasbourg
Employee Range3
Year Founded2022
Last FundingJul 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?